Hosted on MSN3h
For Your Patients: What Is Multiple Myeloma?
Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...
SkylineDx study highlights value in combined myeloma diagnostic approach
SkylineDx’s SKY92 test with fluorescence in situ hybridisation testing led to more accurate identification of high-risk ...
manilatimes2d
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
STUDIO CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month is an annual global awareness campaign that ...
Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Medindia3d
SKYLINEDX ANNOUNCES NEW PUBLICATION ON SKY92 GENE EXPRESSION PROFILING TEST in DEFINING ULTRA-HIGH-RISK MULTIPLE MYELOMA
SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, and inflammatory and infectious diseases, announces ...
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...
Medindia3d
Non-Invasive ctDNA Testing for Early Detection of Multiple Myeloma
Discover how ctDNA revolutionizes multiple myeloma monitoring, tracking disease progression, and improving personalized ...
MedPage Today3d
Multiple Myeloma
Follow along on our guide to Multiple Myeloma, a cancer of the bone marrow's infection-fighting plasma cells. As cancerous ...
Rolling Out6d
A rare cancer, modified cells, and the future they promised
A couple facing a terminal multiple myeloma diagnosis finds renewed hope through innovative immunotherapy, transforming blood ...
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, "CARsgen Therapeutics"), a company focused on innovative CAR ...
This Couple Talks About Navigating a Rare Blood Cancer as a Team
From uncertainty to hope for the future, they offer advice on getting through some of the toughest years of their lives ...